700 per cent multibagger returns: Back-to-back upper circuits in the shares of this small-cap company

The company’s shares have delivered an impressive return of around 188 per cent in the past year to its shareholders.

Shares of Arvee Laboratories (India) were locked in the upper circuit on Tuesday, representing a gain of 10 per cent. The stock has witnessed heavy buying activity from investors in the last few days. Over the last six months, the stock has gained approximately 147.5 per cent.

Incorporated in 2012, Arvee Laboratories India Limited manufactures specialized chemicals.

Share Performance

Today, the company’s shares opened the day at Rs 278 per share on the NSE, hitting an intraday high and low of Rs 278.85 and Rs 260.10 respectively. Currently, it is trading at Rs 278.85 per share on the NSE. Additionally, shares of Arvee Laboratories (India) Limited have delivered multibagger returns of 758 per cent to their shareholders in the last five years. The price fixed during the company's IPO was Rs 61 per share in the year 2018. The company’s shares are among the Top Gainers on the NSE today.

Financial Performance

According to the Quarterly Results, Arvee Laboratories (India) reported a revenue of Rs 7.70 crore, representing a year-on-year decline of 53 per cent from Rs 16.25 crore in the same quarter last year. The operating profit of the company stands at Rs 0.53 crore, with an operating profit margin of 6.88 per cent compared to Rs 1.74 crore in the same quarter last year. The net profit of the company stood at Rs 0.24 crore in the December quarter, a significant improvement compared to a net profit of Rs 0.92 crore same quarter last year.

In terms of ownership, the promoters hold 73.50 per cent of the company, while the public shareholder holds 26.50 per cent.

Company Overview

Arvee Laboratories (India) Limited is an India-based small cap company engaged in the manufacturing of specialized chemicals. The Company's product categories include polymer modifiers, contrast media intermediates, and drug intermediates. Its polymer modifiers products include Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt, and 5-Sodiosulfo-Bis-(B-Hydroxyethyl)-Isophthalate. The Company's contrast media intermediates products include 5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, and 3,5-Diamino Benzoic Acid. Its drug intermediates products include 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine, and 2-Chloro-5-Nitrobenzoic Acid.

The stock has shown tremendous growth and investors should keep a close eye on this stock.

Disclaimer: The article is for informational purposes only and not investment advice.